ASCO: Continuing Avastin With 2nd-Line Chemo Ups Survival

Findings in patients with metastatic colorectal cancer treated with first-line chemo plus Avastin

TUESDAY, June 5 (HealthDay News) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who have progressed after discontinuation of first-line bevacizumab and chemotherapy, according to the results of a phase III study presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Dirk Arnold, M.D., from the University Clinic Eppendorf in Hamburg, Germany, and colleagues randomized 820 patients with unresectable, histologically-confirmed mCRC, who had progressed within three months after discontinuation of first-line bevacizumab plus chemotherapy, to receive second-line fluoropyrimidine-based chemotherapy with bevacizumab (2.5 mg/kg/week equivalent; 409 patients) or without bevacizumab (411 patients). The choice of oxaliplatin- or irinotecan-based second-line chemotherapy was dependent on the regimen used in first-line treatment.

The researchers found that the median OS was significantly longer in those receiving bevacizumab and chemotherapy, compared to those receiving only chemotherapy (11.2 versus 9.8 months; hazard ratio [HR], 0.81), as was median PFS (5.7 versus 4.1 months; HR, 0.68). The adverse event profile was similar to previously reported data for bevacizumab and chemotherapy. When compared with historical data from bevacizumab treatment in first- and second-line mCRC treatment, bevacizumab-related adverse events were not increased by continuing treatment beyond progression.

"By simply switching chemotherapy drugs when the cancer progresses and continuing with bevacizumab, we can make second-line treatment even more powerful," Arnold said in a statement. "This finding will likely spur research into other cancer types that are sensitive to both bevacizumab and chemotherapy."

Several authors disclosed financial ties to pharmaceutical companies, including Genentech/Roche, the manufacturer of bevacizumab.

Abstract
More Information

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Blunt Chest Trauma
Journal of Trauma Nursing, November/December 2014
Expires: 12/31/2016 CE:2 $21.95


The School Age Child with Congenital Heart Disease
MCN, The American Journal of Maternal/Child Nursing, January/February 2015
Expires: 2/28/2017 CE:2.5 $24.95


Understanding multiple myeloma
Nursing Made Incredibly Easy!, January/February 2015
Expires: 2/28/2017 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles

Comprehensive Care: Looking Beyond the Presenting Problem
Journal of Christian Nursing, January/March 2015
Free access will expire on March 2, 2015.


Pain and Alzheimer dementia: A largely unrecognized problem
Nursing Made Incredibly Easy!, January/February 2015
Free access will expire on February 16, 2015.


Glycemic control in hospitalized patients
Nursing2015 Critical Care, January 2015
Free access will expire on February 16, 2015.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events